Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-13
Target enrollment:
Participant gender:
Summary
Breast cancer is a communal malignant disease between Saudi females, with a popularity of
21.8%. Since binding to somatostatin receptors (SSTR) induces no immunogenicity in vivo,
somatostatin analog (veldoreotide) (VELD) may be suitable for delivering anti-cancer drugs to
target and bioimaging the cancer cells. This work aimed to deliver CdS/ZnS core-shell type
quantum dots with carboxylic acid-functionalized (QDs-COOH) which is bioimaging and
anticancer nanoparticles decorated VELD as SSTR agonist with anti-cancer activity in the form
of topical cream to be deposited deep in the breast periphery.